CytoDyn, Inc. (OTCQB: CYDY) is focused on developing new therapies that provide flexibility and freedom to people across the globe who are living with HIV. The company’s lead product, PRO 140, belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection. PRO 140 has several potential benefits including less frequent dosing and minimal side effects that distinguish it from currently used HIV treatments. For more information, visit the company’s website at www.cytodyn.com.